- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01068639
An Observational Study on Treatment Compliance by Children Treated With Growth Hormone (IMPACT)
June 25, 2014 updated by: Novo Nordisk A/S
IMprove PAtient Compliance sTudy: An Observational, Cross-sectional Study on Children Treated With Growth Hormone in France
This study is conducted in Europe.
This observational study aims at evaluating compliance with growth hormone treatment in children and identifying factors influencing compliance.
Study Overview
Status
Withdrawn
Intervention / Treatment
Study Type
Observational
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Children treated for at least one year with growth hormone with any growth hormone product whatever the reason for prescription
Description
Inclusion Criteria:
- Child treated for at least one year with growth hormone any growth hormone product
- Followed by the participating paediatrician for at least 1 year.
Exclusion Criteria:
- Refusal to participate
- Child and/or parent unable to give consent or fill out the questionnaires
- Child participating in a therapeutic trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
A
|
No treatment given to study participants, only behaviorial patterns with respect to treatment compliance is observed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Average number of injections omitted during the previous month
Time Frame: measured over the past 2 months (retrospective data collection)
|
measured over the past 2 months (retrospective data collection)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2010
Primary Completion (Anticipated)
April 1, 2010
Study Completion (Anticipated)
April 1, 2010
Study Registration Dates
First Submitted
February 12, 2010
First Submitted That Met QC Criteria
February 12, 2010
First Posted (Estimate)
February 15, 2010
Study Record Updates
Last Update Posted (Estimate)
June 26, 2014
Last Update Submitted That Met QC Criteria
June 25, 2014
Last Verified
June 1, 2014
More Information
Terms related to this study
Other Study ID Numbers
- GH-3787
- U1111-1113-2490 (Other Identifier: WHO)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Growth Hormone Disorder
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyFrance
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyDenmark
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyGermany
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Growth Hormone Deficiency in ChildrenIsrael, Denmark, Belgium, Spain, Macedonia, The Former Yugoslav Republic of, Turkey, United Kingdom, France, Slovenia, Czech Republic
-
Novo Nordisk A/SCompletedHealthy | Growth Hormone Disorder | Adult Growth Hormone DeficiencyUnited States
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Growth Hormone Deficiency in Children | Delivery SystemsGermany, Netherlands, Sweden
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Adult Growth Hormone DeficiencyGermany
-
Novo Nordisk A/SCompletedHealthy | Growth Hormone DisorderDenmark
-
Novo Nordisk A/SCompletedHealthy | Growth Hormone DisorderGermany
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Growth Hormone Deficiency in Children | Growth Disorder | Idiopathic Short StatureUnited States
Clinical Trials on No treatment given
-
Novo Nordisk A/SEnrolling by invitation
-
Novo Nordisk A/SCompletedObesity and Cardiovascular RiskSaudi Arabia
-
Novo Nordisk A/SEnrolling by invitationObesity | OverweightUnited States, Saudi Arabia, Brazil, Canada, Spain
-
Novo Nordisk A/SCompletedChronic Kidney Disease (CKD) | Atherosclerotic Cardiovascular Disease (ASCVD)India
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompletedObesitySpain, Turkey, Italy, Taiwan, Australia, Colombia, Korea, Republic of, Mexico, Saudi Arabia, United Kingdom
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompletedObesity | Metabolism and Nutrition DisorderUnited States
-
Novo Nordisk A/SCompletedObesity | Metabolism and Nutrition DisorderCanada